HEALTH.2013.0-1
HEALTH.2013.0-1
16 projects · €84,280,958 total EU contribution (project-level) · 72 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€84,280,958
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (12)
- Netherlands (11)
- UK (10)
- SE (8)
- France (7)
- BE (3)
- FI (3)
- Italy (3)
- CH (2)
- DK (2)
- Spain (2)
- HU (2)
- AT (1)
- EL (1)
- IL (1)
- IS (1)
- NO (1)
- PT (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- Leiden University Medical Center4 projects · NL
- ARTTIC2 projects · FR
- PRESENS PRECISION SENSING GMBH2 projects · DE
- 3H Biomedical AB1 projects · SE
- Aber Instruments Lim1 projects · UK
- AMC1 projects · NL
- MOLMED SPA1 projects · IT
- AN1 projects · UK
- AIM1 projects · FR
- astraia1 projects · DE
- Athera1 projects · SE
- AVANTEA1 projects · IT
Projects
Page 2 of 2
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
First in Man Novel Anticancer Therapeutic based on Dependence Receptors Concept HERMIONE-2MAN · 601716 | FP7 | €5,962,231 | €7,750,543 | Details |
Hanging Drop based automated and parallelized cell technology platform for production and testing DROPTECH · 601865 | FP7 | €4,051,319 | €5,228,090 | Details |
Translation of the direct-on-blood PCR-NALFIA system into an innovative near point-of-care diagnostic for malaria DIAGMAL · 601714 | FP7 | €2,652,374 | €3,565,749 | Details |
A new therapeutic antibody with a personalised medicine approach in cardiovascular disease CARDIMMUN · 601728 | FP7 | €5,995,080 | €7,785,840 | Details |
Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer SUPERSIST · 601958 | FP7 | €5,999,997 | €7,892,920 | Details |
Point-of-care tests to revolutionise the clinical management of patients infected by Hepatitis C virus POC-HCV · 601851 | FP7 | €5,991,426 | €8,034,430 | Details |